The company said net revenues for Q1 2024 were $2,366 million, up 1.5% from $2,331 million in Q1 2023. It reported diluted EPS of $1.72, down 3.4% from $1.78 a year earlier, and adjusted diluted EPS of $2.04, flat with the prior year.

1. 01

   The company said net revenues for Q1 2024 were $2,366 million, up 1.5% from $2,331 million in Q1 2023. It reported diluted EPS of $1.72, down 3.4% from $1.78 a year earlier, and adjusted diluted EPS of $2.04, flat with the prior year.

2. 02

   Quest Diagnostics said operating income for Q1 2024 was $300 million, or 12.7% of net revenues, below $305 million (13.1%) a year earlier. Adjusted operating income was $349 million (14.8%). The company cited restructuring and integration charges of $17 million and amortization expense of $29 million among the adjustments.

3. 03

   The company said net cash provided by operating activities for Q1 2024 was $154 million, up 64.8% from $94 million a year earlier. Capital expenditures for the quarter were $104 million, and business acquisitions, net of cash acquired, were $142 million.

4. 04

   The company said it now expects full-year 2024 net revenues of $9.40 billion to $9.48 billion, compared with its prior outlook of $9.35 billion to $9.45 billion. Adjusted diluted EPS is now expected to be $8.72 to $8.97 (prior outlook $8.60 to $8.90), and reported diluted EPS is expected to be $7.57 to $7.82 (prior outlook $7.69 to $7.99).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.